Skip to main content
Figure 6 | Molecular Medicine

Figure 6

From: ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes

Figure 6

Change in corneal nerve density is related to change in PainDetect total score for the ARA 290 treatment group. In subjects having a baseline CNFD >1 SD from the mean of a normal population, improvement in the PainDetect score was related to the change in CNFD at d 28 in the ARA 290 group (panel A) but not in the placebo group (panel B).

Back to article page

Molecular Medicine

ISSN: 1528-3658